Clinical Trials on Platelet Function Tests in Japan
Total 174 results
-
Hamilton Health Sciences CorporationTehran University of Medical Sciences; Tohoku UniversityRecruitingFunctional Dyspepsia | Peptic Ulcer | Gastro Esophageal Reflux | Normal ControlCanada, Iran, Islamic Republic of, Japan
-
MedImmune LLCCompletedGastric or Gastroesophageal Junction AdenocarcinomaCanada, United States, Taiwan, Korea, Republic of, Japan, Singapore
-
SanofiCompletedThrombotic Thrombocytopenic PurpuraJapan
-
Astellas Pharma IncCompleted
-
Toray Industries, IncRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaKorea, Republic of, United States, Japan
-
Baxalta now part of ShireCompletedHereditary Thrombotic Thrombocytopenic Purpura (TTP)United States, Germany, United Kingdom, Switzerland, Austria, Japan, Poland
-
CelgeneActive, not recruiting
-
Eisai Co., Ltd.Completed
-
Alexion Pharmaceuticals, Inc.RecruitingThrombotic MicroangiopathyUnited States, Israel, Korea, Republic of, Spain, Germany, Italy, Japan, United Kingdom, France
-
Bristol-Myers SquibbCompletedHeart Failure | Cardiac Failure | Reduced Ventricular Ejection FractionUnited States, United Kingdom, Japan, Netherlands
-
Novartis PharmaceuticalsTerminatedHeart Failure With Preserved Ejection Fraction (HFpEF)Japan
-
Astellas Pharma IncCompletedMyasthenia GravisJapan
-
Kuhnil Pharmaceutical Co., Ltd.Daiichi Sankyo Co., Ltd.TerminatedGastric Cancer | Gastroesophageal Junction CancerTaiwan, Japan, Korea, Republic of
-
Insel Gruppe AG, University Hospital BernSwiss National Science Foundation; Mach Gaensslen Foundation; Baxalta Innovations...RecruitingThrombotic Thrombocytopenic Purpura | Congenital Thrombotic Thrombocytopenic Purpura | Familial Thrombotic Thrombocytopenic Purpura | Thrombotic Thrombocytopenic Purpura, Congenital | Upshaw-Schulman SyndromeUnited States, Austria, Czechia, Germany, Japan, Norway, Switzerland
-
ShireCompletedEssential Thrombocythemia (ET)Japan
-
Novartis PharmaceuticalsCompletedWell-differentiated Non-functional NET of Thoracic Origin | Well-differentiated Non-functional NET of Gastrointestinal Origin | Well-differentiated Non-functional NET of Pancreatic Origin | Poorly-differentiated Gastroenteropancreatic Neuroendocrine CarcinomaUnited States, Italy, Spain, Japan, Belgium, Netherlands, Germany, France, Canada, Austria, United Kingdom, Australia
-
Bristol-Myers SquibbCompletedLocally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal JunctionFrance, Poland, Russian Federation, Taiwan, United States, Hong Kong, Spain, Germany, Italy, Japan, Korea, Republic of, Singapore
-
PharmaEssentiaMedpace, Inc.; EPS International; Brightech InternationalActive, not recruitingEssential ThrombocythemiaUnited States, Canada, Korea, Republic of, China, Hong Kong, Singapore, Taiwan, Japan
-
Astellas Pharma Global Development, Inc.RecruitingPancreatic Adenocarcinoma | Gastric Adenocarcinoma | Gastroesophageal Junction (GEJ) AdenocarcinomaUnited States, Japan, Korea, Republic of
-
Sobi, Inc.Active, not recruitingEvaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITPImmune ThrombocytopeniaJapan
-
Alexion Pharmaceuticals, Inc.RecruitingThrombotic MicroangiopathyUnited States, Italy, Spain, Korea, Republic of, United Kingdom, Belgium, Netherlands, Germany, Japan, Greece, Brazil, Israel, France, China, Sweden, Australia, Canada, Poland
-
PfizerTerminatedPrimary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia MyelofibrosisUnited States, Japan
-
Eisai Inc.CompletedThrombocytopenia Associated With Liver DiseaseUnited States, China, Spain, Argentina, Belgium, Israel, Mexico, Romania, Japan, Brazil, Russian Federation, Germany, Italy, Czechia, Canada, Australia, France
-
AmgenRecruitingGastric Cancer | Gastroesophageal Junction CancerJapan, Korea, Republic of, Taiwan, Singapore, United States
-
AstraZenecaRecruitingGastric Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Adenocarcinoma | Gastro-esophageal Junction CancerKorea, Republic of, United States, Japan, Taiwan, China, United Kingdom, Netherlands
-
Eli Lilly and CompanyCompletedMetastatic Gastric Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaKorea, Republic of, Taiwan, Japan
-
AstraZenecaCompletedStomach Neoplasms | Small Cell Lung Carcinoma | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Triple Negative Breast Neoplasms | Esophageal Squamous Cell Carcinoma | Carcinoma, Pancreatic Ductal | Carcinoma, Squamous Cell of Head and Neck | Esophagogastric Junction NeoplasmsKorea, Republic of, Japan
-
ShireCompletedEssential Thrombocythemia (ET)Japan
-
Astellas Pharma Global Development, Inc.Active, not recruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaUnited States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
-
CytokineticsCompletedHeart Failure With Reduced Ejection FractionJapan
-
Astellas Pharma IncCompletedDiarrhea-predominant Irritable Bowel SyndromeJapan
-
Merck Sharp & Dohme LLCRecruitingEssential ThrombocythemiaPoland, Israel, Australia, Hong Kong, Japan, New Zealand, Taiwan, Korea, Republic of, United States, Spain, Italy, Netherlands, Germany, France, Sweden, Turkey
-
BeiGeneActive, not recruitingGastric, or Gastroesophageal Junction AdenocarcinomaUnited States, China, Spain, Korea, Republic of, Poland, Russian Federation, Taiwan, France, Turkey, Japan, Italy, United Kingdom, Puerto Rico
-
AstraZenecaRecruitingHeart Failure and Impaired Kidney FunctionSpain, France, Germany, Italy, United States, Argentina, Czechia, Vietnam, Peru, China, Philippines, Saudi Arabia, Australia, Austria, Canada, Japan, Malaysia, Poland, Taiwan, Thailand, Israel, Brazil, Finland, Greece, Mexico, United Kingdom and more
-
Alexion Pharmaceuticals, Inc.TerminatedThrombotic MicroangiopathyUnited States, Belgium, France, Italy, Japan, Spain, Taiwan, United Kingdom, Canada, Korea, Republic of, Netherlands
-
AstraZenecaActive, not recruitingGastrointestinal Neoplasms | Esophagogastric JunctionBelgium, Denmark, Spain, United Kingdom, Canada, United States, Taiwan, Turkey, France, Germany, Korea, Republic of, Brazil, Hungary, Japan, Peru, Poland, Russian Federation, Netherlands, Chile, Argentina
-
UCB Biopharma SRLTerminatedPrimary Immune ThrombocytopeniaUnited States, China, Georgia, Germany, Hungary, Italy, Japan, Moldova, Republic of, Poland, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom
-
Novartis PharmaceuticalsCompletedPrimary Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis | Post-Polycythemia Vera-MyelofibrosisBelgium, Italy, Spain, Bulgaria, Turkey, Greece, Russian Federation, Austria, Canada, Japan, Germany
-
Astellas Pharma Global Development, Inc.Active, not recruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaUnited States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
-
UCB Biopharma SRLTerminatedPrimary Immune ThrombocytopeniaUnited States, Bulgaria, France, Georgia, Greece, Hungary, Italy, Japan, Korea, Republic of, Moldova, Republic of, Poland, Romania, Russian Federation, Taiwan, Ukraine, United Kingdom
-
Novartis PharmaceuticalsCompleted
-
AstraZenecaTerminatedGastric Cancer | Gastro-oesophageal Junction CancerBulgaria, Czech Republic, Italy, Korea, Republic of, Spain, United Kingdom, Hungary, Romania, Ukraine, Belgium, Canada, Germany, Taiwan, India, Japan, France
-
Novartis PharmaceuticalsCompletedAsian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MFPrimary Myelofibrosis (MF) | Post-Polycythemia Vera (PV) MF | Post-Essential Thrombocythemia (ET) MFTaiwan, Japan, Korea, Republic of, China
-
Incyte CorporationRecruitingAnemia | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisUnited States, France, Italy, Japan, United Kingdom, Canada
-
Chugai PharmaceuticalNot yet recruitingAntiphospholipid Syndrome (APS) | Immune Thrombocytopenia (ITP) | Dermatomyositis (DM) | Bullous Pemphigoid (BP) | Behçet's Syndrome (BS) | Immune-mediated Necrotizing Myopathy (IMNM)United States, Japan
-
Janssen Research & Development, LLCRecruitingMyasthenia GravisUnited States, Japan, Netherlands, Poland
-
AstraZenecaCompletedHeart Failure With Reduced Ejection Fraction (HFrEF)United States, Canada, Denmark, Korea, Republic of, Brazil, Slovakia, Japan, South Africa, Sweden
-
Baxalta now part of ShireCompletedVon Willebrand DiseaseNetherlands, Spain, United States, Belgium, Australia, United Kingdom, Austria, Italy, Bulgaria, Japan, Poland, Germany, India, Canada, Russian Federation, Sweden
-
Baxalta now part of ShireTakeda Development Center Americas, Inc.CompletedThrombotic Thrombocytopenic Purpura (TTP)United States, Spain, Germany, Italy, Poland, Japan, Austria, United Kingdom, France
-
TakedaActive, not recruitingPrimary Immune ThrombocytopeniaSpain, United States, Croatia, Italy, China, Germany, Bulgaria, Greece, Slovenia, Japan, Ukraine